Literature DB >> 9171872

1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2.

I K Khanna1, R M Weier, Y Yu, P W Collins, J M Miyashiro, C M Koboldt, A W Veenhuizen, J L Currie, K Seibert, P C Isakson.   

Abstract

Series of 1,2-diarylpyrroles has been synthesized and found to contain very potent and selective inhibitors of the human cyclooxygenase-2 (COX-2) enzyme. The paper describes short and practical syntheses of the target molecules utilizing the Paal-Knorr reaction. Electrophilic substitution on 1 proceeds in a regioselective fashion, and the method was used to generate a number of tetrasubstituted pyrroles. Detailed SAR on the series has been studied by modifications of the aryl rings and the substituents in the pyrrole ring. Diarylpyrrole 1 is a very potent (COX-2, IC50 = 60 nm) and selective (COX-1/COX-2 = > 1700) inhibitor whereas the isomeric 2 is completely inactive against COX-2. Modifications of the substituents on the fluorophenyl ring in 1 yields very potent inhibitors of COX-2 (IC50 = 40-80 nm) with excellent selectivity (1200 to > 2500) vs COX-1. Analog 20 containing a sulfonamide group is an excellent inhibitor of COX-2 with an IC50 of 14 nm. Tetrasubstituted pyrroles containing groups such as COCF3, SO2CF3, or CH2OAr at position 3 in the pyrrole ring give excellent inhibitors (COX-2, IC50 = 30-120 nm). In vivo testing in the carrageenan-induced paw edema model in the rat establishes that the 1,2-diarylpyrroles are orally active antiinflammatory agents. Compound 3 is the most potent inhibitor of edema with an ED50 of 4.7 mpk.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171872     DOI: 10.1021/jm970036a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

2.  Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst.

Authors:  Madhu Chopra; Ruby Gupta; Swati Gupta; Daman Saluja
Journal:  J Mol Model       Date:  2008-07-30       Impact factor: 1.810

Review 3.  Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.

Authors:  N M Davies; A J McLachlan; R O Day; K M Williams
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

4.  Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation.

Authors:  F Nantel; D Denis; R Gordon; A Northey; M Cirino; K M Metters; C C Chan
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions.

Authors:  Kyaw-Zeyar Myint; Lirong Wang; Qin Tong; Xiang-Qun Xie
Journal:  Mol Pharm       Date:  2012-08-31       Impact factor: 4.939

6.  Synthesis of 2-(N-Benzylpyrrolyl)-benzimidazoles Using Polyphosphoric Acid Prompted Cyclocondensation.

Authors:  Bereket Mochona; Laine Le; Madhavi Gangapuram; Nelly Mateeva; Tiffany Ardley; Kinfe K Redda
Journal:  J Heterocycl Chem       Date:  2010-11-01       Impact factor: 2.193

7.  One-step continuous flow synthesis of highly substituted pyrrole-3-carboxylic acid derivatives via in situ hydrolysis of tert-butyl esters.

Authors:  Ananda Herath; Nicholas D P Cosford
Journal:  Org Lett       Date:  2010-10-21       Impact factor: 6.005

8.  Ligand biological activity predictions using fingerprint-based artificial neural networks (FANN-QSAR).

Authors:  Kyaw Z Myint; Xiang-Qun Xie
Journal:  Methods Mol Biol       Date:  2015

9.  Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.

Authors:  A A Shah; B Thjodleifsson; F E Murray; E Kay; M Barry; G Sigthorsson; H Gudjonsson; E Oddsson; A B Price; D J Fitzgerald; I Bjarnason
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

10.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.